



E-ISSN: 2616-3470
P-ISSN: 2616-3462
© Surgery Science
www.surgeryscience.com
2019; 3(1): 81-84
Received: 16-11-2018
Accepted: 19-12-2018

Dr. Shakeel Masood
Additional Professor,
Department of Surgical
Gastroenterology Dr. Rmlims
Lucknow, Uttar Pradesh, India

Dr. Utkarsh Srivastava
Senior Resident,
Department of Surgical
Gastroenterology Dr. Rmlims
Lucknow, Uttar Pradesh, India

Dr. Ravi Gupta
Senior Resident,
Department of Surgical
Gastroenterology Dr. Rmlims
Lucknow, Uttar Pradesh, India

Solid pseudopapillary neoplasms of the pancreas clinical analysis of 8 cases from North India and review literature

Dr. Shakeel Masood, Dr. Utkarsh Srivastava and Dr. Ravi Gupta

DOI: <https://doi.org/10.33545/surgery.2019.v3.i1b.17>

Abstract

Solid pseudopapillary neoplasm (SPN) is rare pancreatic neoplasm. Predominantly in young female, present with abdominal lump and pain. These tumors are indolent in nature. In our case series, 8 cases in 6 years period (2012 to 2018), with one of them is unusual site in retroperitoneum. Mean age of presentation was 25.6 years. Presenting symptom was dull aching pain (80%), lump in upper abdomen (65%). Mean size was 11.6 cm on imaging abdomen. All patients underwent surgery, one patient underwent preoperative FNAC due to unusual location. Mean postoperative hospital stay was 13.9 days with no mortality. By immunohistochemistry, all cases stained positive for vimentin, CD 10 and all were negative for cytokeratin and Ki67 <2 % .Mean follow up period of 57 months, with no recurrence and metastasis. Rarely these can also present at unusual site like retroperitoneum. After surgery patients have good long term survival.

Keywords: Solid pseudopapillary neoplasm (SPN), pancreas, clinical analysis, surgery, follow up, retroperitoneal SPN

Introduction

Solid pseudo papillary neoplasm (SPN) of the pancreas is a rare neoplasm with low malignant potential with unknown etiology, which represents 1-2% of pancreatic exocrine cancers and 5% of cystic pancreatic tumours [1-3]. Papillary cystic neoplasm was the first name given to this tumor by Virginia Frantz in 1959 [4]. Later on in 1970 Hamoudi separated it different entity on finding of the electron microscopic features of tumor [5]. SPN is classified as low malignant potential tumor of exocrine pancreas according to WHO classification given in 1996 [6]. At present, term SPN is most widely used for this tumor [7].

In recent few years the detection of incidental small lesion of pancreas has been increased with the advent of high resolution no invasive imaging technique. So the incidental pancreatic lesion is around 0.2-0.7% in recent publication [8]. But still there is debate on etiology [7]. In our case series we are presenting clinical and histopathological features, immunohistochemistry and treatment, followed by discussion with review of literature.

Materials and Methods

Total 8 patient records were obtained by retrospective analysis from year 2012 to 2018 (6 years). All patients were females. As a imaging, triphasic CECT (pancreatic protocol) was done in all cases. CT guided FNAC was done in 1 patient with a unusual location, that was in retroperitoneum. The clinico-pathological, radiological, operative and survival data were obtained and analyzed. Follow up was done in all patients, 6 monthly for 2 years and then annually thereafter. Clinical evaluations, routine blood investigations, serum CEA, CA19-9, CECT abdomen and chest were done in follow up.

Results

Total patients were 8 and all were females with age group from 20 to 35 years (mean 25.6 years). 80% patient had dull aching pain in upper abdomen, 65% had lump in upper abdomen and 16% presented with early satiety. As location wise most common site was tail 37.5%, head and body with 25% each and one (12.5%) in retroperitoneum. On imaging mean size of tumor was 11.6 cm. All patients underwent surgery. Patients with head mass underwent classical pancreaticoduodenectomy. Patient with tail and body mass underwent distal pancreatectomy with splenectomy, one patient underwent enucleation of mass from retroperitoneum.

Correspondence
Dr. Ravi Gupta
Senior Resident,
Department of Surgical
Gastroenterology Dr. Rmlims
Lucknow, Uttar Pradesh, India

Mean hospital stay were 13.9 days. 2 patients (25%) developed grade A POPF (postoperative pancreatic fistula) , 2 patients (25%) developed grade A DGE (delayed gastric emptying). 1 patient (12.5%) had grade B POPF which was managed conservatively .There were no postoperative mortality .Patients were follow up with mean of 57 months with no recurrence or metastasis.



Fig 1.1: CECT scan of the abdomen showing the solid cystic lesion in the pancreatic tail and an area of cystic degeneration is noted centrally.



Fig 1.2: The specimen has been resected en bloc with the spleen through an open approach.



Fig 2.1: USG abdomen showing well encapsulated solid cystic lesion in head pancreas.



Fig 2.2: CECT scan of the abdomen showing the solid cystic lesion in the pancreatic head, abutting the portal vein and central cystic degenerated area seen.




Fig 2.3: The specimen of classical whipples procedure having head mass.




Fig 3.1: CECT abdomen revealing mass in retroperitoneum close to pancreatic tail and left kidney with cystic degeneration and multiple septa with peripheral enhancement.




Fig 3.2: Open midline incision given through mass has been enucleated and removed.



Fig 3.3: Excised specimen of mass, well encapsulated.

Discussion

Solid pseudopapillary tumor are rare neoplasm of pancreas but recent advancement in imaging had lead to increase the prevalence of the disease [8]. It generally has a good prognosis after complete surgical resection [9].

More common in young females. A study of 718 patients having SPN showed that the head and tail disease is predominant site (more than 90%), with average age of 22 years [10]. In our study all patients were females and most common site was body and tail (fig 1.1, 1.2) followed by head (fig 2.1, 2.2, 2.3) and one at unusual location retroperitoneum (fig 3.1, 3.2, 3.3).

There is dilemma about the origin of these tumor. Due to it female predominant nature, its origin is attributed to primordial pancreatic cells to the ovarian ridge during development [11].

Radiologically CECT and MRI both are almost equally diagnostic, MRI is slightly better than CT in identifying capsule, hemorrhage and cystic degeneration [12]. On CT scan these tumor are well encapsulated, hypodense with various solid cystic components [12]. On MRI feature are well defined lesions with high and low signal intensity on T1 and high signal intensity on T2 [12]. In our study triphasic CECT was done in all cases.

As the site is concern, this tumor involve any part of pancreas in which head and tail are more common locations [10, 13]. A study of 718 patients with SPN showed that most common site is tail 35.9% followed by head 34% and 10.3% in body and tail and least common and rare extra pancreatic site 1% [10]. In our study pancreatic tail was most common site and 1 case of retroperitoneal SPN was also present.

Symptom with which patients present are of vague type which include increased abdominal girth, abdominal discomfort, abdominal pain, poor appetite, and nausea. These symptoms are due to involvement of adjacent organ stomach. Dull pain was most common symptoms in around 80% then followed by lump in upper abdomen in 65% in our study.

On gross these tumor are well encapsulated (fig 1.2, 2.3, 3.3). On microscopic examination there is solid cystic mass with center of hemorrhagic and necrotic material and peripherally by solid tissue [14]. Pseudopapillary formation, foamy histiocytes, nuclear groove are characteristic finding of SPN [17]. On IHC they are characteristically positive for alpha 1-antitrypsin, CD56, CD10, and vimentin are present in 90% of patients [11]. In our study all the patients were stained strongly for vimentin, CD 10 and all were negative for cytokeratin and Ki 67 <2%.

Malignant transformation is more common in elderly males. 15% of adults and 13% of children are at risk of malignant transformation [12, 15]. On histology feature of malignant tumor are angioinvasion, perineural invasion, and deep pancreatic tissue invasion [12]. 10 to 15 % patient have metastasis to liver, lymph nodes and peritoneum [7, 12, 16, 17]. Tumor size more than 5 cm, angioinvasion are poor prognostic factors [7, 17, 18]. 5 year survival rate after complete resection of tumor is more than 95%, so even in the presence of local invasion, limited metastasis and recurrence complete resection is done [1, 7, 16]. In our study mean follow up was 57 months with no recurrence or distant metastasis. Surgical debulking is also done and in contrast to other pancreatic neoplasm this tumor is resected even after portal vein and superior mesenteric artery involvement [19, 20, 21].

Role of adjuvant therapy is unclear in SPN. Some study had shown role of gemcitabine and radiotherapy to downstage the tumor [22, 23].

Conclusion

Pancreatic SPNs are rare neoplasms with malignant potential. Primarily it is a young women disease. Differential diagnosis should be kept in mind when a young women present with pancreatic mass. FNAC has a role if there is dilemma in diagnosis. Surgical resection provide curative treatment with excellent long term prognosis. So patients with SPN should be treated aggressively with complete resection to achieve long term survival.

References

1. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in the English literature. *J Am Coll Surg*. 2005; 2:965-72.
2. Tang LH, Aydin H, Brennan MF, Klimstra DS. Clinically aggressive solid pseudopapillary tumor of pancreas: A report of cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. *Am J Surg Pathol*. 2005; 29:51-2.
3. De Castro SM, Singhal D, Aronson DC, Busch OR, van Gulik TM, Obertop H *et al*. Management of solid-pseudopapillary neoplasms of the pancreas: a comparison with standard pancreatic neoplasms. *World J Surg*. 2007;

- 31:1129-34.
4. Frantz VK. Tumors of the pancreas. In: Bumberg CW, editors. Atlas of Tumor Pathology, VII Fascicles 27 and 28. Washington, DC: Armed Forces Institute of Pathology, 1959, 32-33.
5. Hamoudi AB, Misugi K, Grosfeld JL, Reiner CB. Papillary epithelial neoplasm of pancreas in a child. Report of a case with electron microscopy. *Cancer*. 1970; 26:1126-30.
6. Kloppel G, Solcia E, Longnecker DS, Capella C *et al*. Histological typing of tumors of the exocrine pancreas. In: World Health Organisation International Histological Classification of Tumors. 2nd ed. Berlin, Heidelberg, New York: Springer, 1996, 8452/1.
7. Martin RC, Klimstra DS, Brennan MF, Conlon KC. Solid-pseudopapillary tumor of pancreas: A surgical enigma? *Ann Surg Oncol*. 2002; 9:35-40.
8. Edirimanne S, Connor SJ. Incidental pancreatic cystic lesions. *World J Surg*. 2008; 32:2028-37.
9. Saiura A, Umekita N, Matsui Y *et al*. Successful surgical resection of solid cystic tumor of the pancreas with multiple liver metastases and a tumor thrombus in the portal vein. *Hepatogastroenterology*. 2000; 47:887-9.
10. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. *J Am Coll Surg*. 2005; 200:965-72.
11. Kosmahl M, Seada L, Janig U *et al*. Solid pseudopapillary tumor of the pancreas: its origin revisited. *Virchows Arch*. 2000; 436:473-80.
12. Zhang H, Liang T, Wang W *et al*. Diagnosis and treatment of solid pseudo papillary tumor of the pancreas. *Pancreas* 2006; 5(3):454-8.
13. Pettinato G, Manivel JC, Ravetto C *et al*. Papillary cystic tumor of the pancreas: a clinicopathologic study of 20 cases with cytologic, immunohistochemical, ultra structural, and flow cytometric observations, and a review of literature. *Am J Clin Pathol*. 1992; 5:478-88.
14. Dong D, Zhang S. Solid pseudopapillary tumor of the pancreas: CT and MRI features of 3 cases. *Hepatobiliary and Pancreatic Diseases International*. 2006; 5(2):300-4.
15. Machado CM, Machado AM, Bacchella T, Jukemura J *et al*. Solid pseudopapillary neoplasm of the pancreas: distinct patterns of onset, diagnosis, and prognosis for male versus female patients. *Surgery*, 2008, 29-34.
16. Reddy S, Cameron J, Scudiere J, Hruban R *et al*. Surgical management of solid pseudopapillary neoplasms of the pancreas (Franz or Hamoudi Tumors): A large single institutional series. *Journal Am Coll Surg*. 2009; 208(5):950-7.
17. Kang C, Kim K, Choi J, Kim H *et al*. Solid pseudopapillary tumor of the pancreas suggesting malignant potential. *Pancreas*. 2006; 32(3):276-80.
18. Nishihara K, Nagoshi M, Tsuneyoshi M *et al*. Papillary cystic tumors of the pancreas: assessment of their malignant potential. *Cancer*. 1993; 71:8292.
19. Hassan I, Celik I, Nies C *et al*. Successful treatment of solid pseudopapillary tumor of the pancreas with multiple liver metastases. *Pancreatol*. 2005; 5:289-94.
20. Alexandrescu D, O'Boyle K, Feliz A *et al*. Metastatic solid pseudopapillary tumor of the pancreas: clinicobiological correlates and management. *Clin Oncol*. 2005; 17:358-63.
21. Decastro S, Singhal D, Aronson D *et al*. Management of solid pseudopapillary neoplasms of the pancreas: a comparison with standard pancreatic neoplasms. *World J Surg*. 2007; 31:1130-5.
22. Maffuz A, Bustamante F, Silva J, Torres Vargas S. Preoperative gemcitabine for unresectable, solid pseudopapillary tumor of the pancreas. *Lancet Oncol*. 2005; 6:185-6.
23. Fried P, Cooper J, Balthazar E *et al*. A role for radiotherapy in the treatment of solid and papillary neoplasms of the pancreas. *Cancer*. 1985; 56:2783-5.